About Disc Medicine
Disc Medicine is a company based in Cambridge (United States) founded in 2017 by Brian Mac Donald. Disc Medicine has raised $140 million across 4 funding rounds from investors including ARE, Orbimed and Janus Henderson Investors. The company has 84 employees as of December 31, 2024. Disc Medicine offers products and services including Bitopertin, DISC-0974, and DISC-3405. Disc Medicine operates in a competitive market with competitors including Freeline, Keros Therapeutics, Jasper Therapeutics, Interius Biotherapeutics and China Biologic Products Holdings, among others.
- Headquarter Cambridge, United States
- Employees 84 as on 31 Dec, 2024
- Founders Brian Mac Donald
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Disc Medicine, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$109.36 M (USD)-43.08as on Dec 31, 2024
-
EBITDA
-$129.56 M (USD)-42.34as on Dec 31, 2024
-
Total Equity Funding
$140 M (USD)
in 4 rounds
-
Latest Funding Round
$62.5 M (USD), Post-IPO
Feb 14, 2023
-
Investors
ARE
& 11 more
-
Employee Count
84
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Disc Medicine
Disc Medicine is a publicly listed company on the NASDAQ with ticker symbol IRON in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Disc Medicine
Disc Medicine offers a comprehensive portfolio of products and services, including Bitopertin, DISC-0974, and DISC-3405.
Drug for treating erythropoietic protoporphyria by reducing PPIX levels
Candidate for hematologic diseases through targeted development
Therapy in development for blood disorder applications
People of Disc Medicine
Unlock access to complete
Unlock access to complete
Funding Insights of Disc Medicine
Disc Medicine has successfully raised a total of $140M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $62.5 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Disc Medicine
Disc Medicine has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Orbimed and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Investment and holding company controlled by Len Blavatnik
|
Locked | Locked | Locked |
Investor details for Disc Medicine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Disc Medicine
Investment portfolio details for Disc Medicine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Disc Medicine
Detailed financials for Disc Medicine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Disc Medicine Comparisons
Peer comparison for Disc Medicine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Disc Medicine
Disc Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, Keros Therapeutics, Jasper Therapeutics, Interius Biotherapeutics and China Biologic Products Holdings, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
|
| Locked | Locked | Locked |
Small molecules are developed to treat hematologic and musculoskeletal disorders.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating multiple diseases
|
|
| Locked | Locked | Locked |
Human plasma-based biopharmaceutical products are developed and commercialized.
|
Detailed competitors of Disc Medicine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Disc Medicine
Complete news archive for Disc Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Disc Medicine
Disc Medicine was founded in 2017.
Disc Medicine is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Brian Mac Donald is the current CEO of Disc Medicine. They have also founded this company.
Disc Medicine is a funded company, having raised a total of $140M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Disc Medicine is 84.
Disc Medicine was founded in 2017 and is headquartered in Cambridge, United States. Focus is placed on developing therapeutic candidates that target fundamental pathways in red blood cell biology to address hematologic diseases. The product pipeline features Bitopertin, intended for erythropoietic porphyrias; DISC-0974, aimed at anemia associated with myelofibrosis; and matriptase-2, designed for myelodysplastic syndromes. Operations center on advancing these candidates through clinical development in the biotechnology sector.
Disc Medicine's top competitors include Keros Therapeutics, Freeline and Jasper Therapeutics.
Disc Medicine offers Bitopertin, DISC-0974, and DISC-3405.
Yes, Disc Medicine is publicly traded on NASDAQ under the ticker symbol IRON.
Disc Medicine has 12 investors. Key investors include ARE, Orbimed, Janus Henderson Investors, Atlas Venture, and Arix Bioscience.
The ticker symbol of Disc Medicine is IRON on NASDAQ.